Evaluating Immunome: Insights From 4 Financial Analysts
Portfolio Pulse from Benzinga Insights
In the past three months, four analysts have provided ratings for Immunome (NASDAQ:IMNM), ranging from bullish to bearish. The average 12-month price target is $29.75, with a high of $35.00 and a low of $24.00. Recent ratings include 'Overweight' from Piper Sandler and JP Morgan, 'Buy' from Guggenheim, and 'Outperform' from Wedbush. Immunome, a biopharmaceutical company, has faced a revenue decline of -56.47% and has a net margin of -12584.26%.
May 31, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Immunome has received mixed ratings from analysts, with an average price target of $29.75. The company faces significant revenue decline and negative net margins, which may impact its stock price.
The mixed analyst ratings and significant revenue decline suggest a neutral short-term impact on Immunome's stock price. While the average price target is higher than the current price, the company's financial challenges may offset potential gains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100